Decipher is now part of Veracyte!     Learn More
Decipher is now part of Veracyte!     Learn More
Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 2, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare
View HTML
Toggle Summary Veracyte Appoints Muna Bhanji to Its Board of Directors
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 22, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Muna Bhanji , R.Ph., a global senior healthcare executive, to its board of directors, effective immediately.
View HTML

Events

Date Event Details
Summary Toggle Apr 13, 2021 2:15 PM EDT
20th Annual Needham Virtual Healthcare Conference

Presentations

Title Documents

Corporate Presentation April 2021